Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Indonesian Journal of Endocrinology Metabolism and Diabetes (InaJEMD)
Eva Niamuzisilawati
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
A Rare Coexistence of Thyrotoxic Cardiomyopathy and Asthma in Graves’ Disease: Clinical Challenges and Management Strategies: A Case Report Mutiara Lirendra; Eva Niamuzisilawati; Ega Caesaria; Brilliant Van Fitof; A Farih Raharjo; Adi Bestara
‎ InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes Vol. 2 No. 2 (2025): InaJEMD Vol. 2, No. 2
Publisher : PP PERKENI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.66266/inajemd.v2i2.64

Abstract

Graves' disease is the most common autoimmune hyperthyroid disorder. Thyrotoxic cardiomyopathy (TCM) is a rare but potentially lethal complication of thyrotoxicosis, with an incidence of <1%. Betablocker is one of the drugs of choice in treating TCM. However, in asthma patient, beta-blocker may induce bronchoconstriction. We report a rare case of a 36-year-old male presented with complaints of shortness of breath, wheezing, cough, and palpitation. The patient had a history of asthma. Physical examination revealed diffuse thyroid enlargement, exophthalmos, tremor, cardiomegaly, irregular heart sounds, rales, wheezing in both lungs, and BMI was underweight. Wayne index was 20 (hyperthyroid) and Burch Wartofsky score was 35 (impending storm). Laboratory results showed low Thyroid-stimulating hormone level and high level of Free-T3, Free-T4, Thyroid-Stimulating Hormone Receptor Antibodies, and N-terminal pro-B-type natriuretic peptide. Chest X-ray showed cardiomegaly. electrocardiogram showed atrial fibrillation RVR. Echocardiography showed segmental wall motion abnormality EF 48%. Patient was diagnosed with Graves’ disease with hyperthyroidism, acute asthma exacerbation, Heart failure with mildly reduced ejection fraction NYHA III due to thyrotoxic cardiomyopathy. Patient was treated with methimazole, shortacting beta-agonists, corticosteroid, digitalis, diuretics, anticoagulant, and angiotensin receptor blockers. During follow up, laboratory results, ECG, and clinical symptoms were improved. The management of Graves' disease with hyperthyroidism and TCM focuses primarily on controlling the thyroid hormone levels to prevent further cardiac deterioration. The complex interplay between managing thyroid hormone levels and preventing asthma exacerbation in this patient highlights the need for a multidisciplinary approach to optimize treatment outcomes. Graves' hyperthyroid patients with cardiomyopathy and asthma require holistic, comprehensive, and meticulous drug selection to prevent exacerbation.
Fibrocalculous Pancreatic Diabetes (FCPD): A Rare Type of Pancreatogenic Diabetes Ega Caesaria Pratama Putra; Eva Niamuzisilawati; Yulia Sekarsari; Brilliant Van Fitof Songso Rhomado; Supriyanto Kartodarsono
‎ InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes Vol. 2 No. 2 (2025): InaJEMD Vol. 2, No. 2
Publisher : PP PERKENI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.66266/inajemd.v2i2.68

Abstract

FCPD is a rare form of secondary diabetes. FCPD is mainly found in the tropical region; it is characterized by diabetes, chronic abdominal pain, calcification of the pancreas, and steatorrhea. The Incidence of FCPD is often misdiagnosed with type 2 or type 1 diabetes mellitus. A 46-year-old man came with chief complaints of chronic abdominal pain. Abdominal radiography showed calcification in the pancreas. The patient was malnourished. Abdominal X-ray revealed pancreatic calcification, which was confirmed by an abdominal MSCT scan. C-Peptide decreased with an intermediate degree. The patient was given supportive therapy,and insulin was given to control his diabetes. FCPD is a morphological pancreas change caused by chronic tropical pancreatitis. The aetiology of chronic tropical pancreatitis is unknown. FCPD can be diagnosed by history taking and supporting examinations such as abdominal X-ray examination, ultrasound and abdominal CT Scan. C-peptide was examined to assess the function of pancreatic beta cells. The primary treatment for FCPD is insulin therapy; metformin or Sulfonylureas can be used in the early phase of diabetes. In reducing pain, non-steroidal analgesics are used as an option. The use of pancreatic enzyme supplementation can improve the nutritional status of patients. FCPD is a rare case, occurring mainly in tropical countries and in people who are malnourished. The primary treatment for FCPD is insulin therapy.
Co-Authors A Farih Raharjo Adi Bestara Brilliant Van Fitof Brilliant Van Fitof Songso Rhomado Ega Caesaria Ega Caesaria Pratama Putra Mutiara Lirendra Supriyanto Kartodarsono Yulia Sekarsari